seekingalpha.com · 3 jul

Abbott Laboratories Q2 Earnings Preview: A Contrarian Buy Opportunity Worth Considering

Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.

247wallst.com · 2 jul

5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential

Passive income is characterized by its ability to generate revenue without requiring the earner's continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence.

fool.com · 1 jul

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics, nutrition, and generic medicines. Intuitive Surgical maintains a dominant position in robotic-assisted surgery with a high-margin, recurring revenue business model.

247wallst.com · 1 jul

Here Are Wednesday's Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More

Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up 0.26% to finish the venerable index's best first half since 2021, while the Nasdaq finished the session at 26,213, up 1.52% for the tech-heavy index's best quarterly finish since 2020.

benzinga.com · 1 jul

This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

zacks.com · 29 jun

Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.

marketwatch.com · 29 jun

Value stocks beat growth when inflation is high. Here are 13 stocks top newsletters are betting on now.

This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks beating growth stocks.

fool.com · 29 jun

3 No-Brainer Dividend Stocks to Buy Right Now

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.